Table 4.
Potential variables affecting the antibody production and common systemic side effects based on detection of SARS-CoV-2 RBD and SARS-CoV-2 neutralizing antibody.
| Potential variables affecting the antibody production and common systemic side effects | SARS-CoV-2 RBD antibody positive after dose 1 (N = 219) N (%) |
SARS-CoV-2 RBD antibody negative after dose 1 (N = 19) N (%) |
P value | SARS-CoV-2 RBD antibody positive after dose 2 (N = 200) N (%) |
SARS-CoV-2 RBD antibody negative after dose 2 (N = 5) N (%) |
P value | SARS-CoV-2 neutralizing antibody positive after dose 2 (N = 186) N (%) |
SARS-CoV-2 neutralizing antibody negative after dose 2 (N = 18) N (%) | P value |
|---|---|---|---|---|---|---|---|---|---|
| Demographic features and history of COVID-19 | |||||||||
| Female | 142 (64.86) | 10 (52.6) | 0.324 | 128 (64) | 3 (60) | 1 | 119 (64) | 11 (61.1) | 0.802 |
| Male | 77 (35.2) | 9 (47.4) | 72 (36) | 2(40) | 67 (36) | 7 (38.9) | |||
| ≤ 38 years old | 119 (54.3) | 10 (52.6) | 1 | 107 (53.5) | 2(40) | 0.667 | 100 (53.8) | 9 (50) | 0.808 |
| > 38 years old | 100 (45.7) | 9 (47.4) | 93 (46.5) | 3 (60) | 86 (46.2) | 9 (50) | |||
| *Past COVID-19 infection | 56 (25.6) | 1 (5.3) | 0.04 | 51 (25.5) | 0 | 0.335 | 50 (26.9) | 0 | 0.008 |
| Common systemic side effects | |||||||||
| Fever | 57 (26) | 4 (21) | 0.788 | 34 (17) | 0 | 0.593 | 31 (16.7) | 3 (16.7) | 1 |
| Chilling | 51 (23.3) | 7 (36.8) | 0.262 | 35 (17.5) | 0 | 0.591 | 33 (17.2) | 2 (11.2) | 0.744 |
| Headache | 63 (28.8) | 6 (31.1) | 0.795 | 50 (25) | 2 (40) | 0.603 | 46 (24.7) | 6 (33.3) | 0.4.8 |
| Body pain | 89 (40.6) | 8 (42.1) | 1 | 62 (31) | 0 | 0.325 | 59 (31) | 3 (16.7) | 0.283 |
| Fatigue | 95 (43.4) | 8 (42.1) | 1 | 72 (36) | 0 | 0.164 | 66 (35.5) | 6 (33.3) | 1 |
| Weakness | 71 (32.4) | 7 (36.8) | 0.800 | 62 (31) | 1 (20) | 1 | 57 (30.6) | 6 (33.3) | 0.794 |
| Joint pain | 56 (25.6) | 1 (5.3) | 0.051 | 40 (20) | 0 | 0.585 | 37 (19.9) | 3 (16.7) | 1 |
| Other vaccinations** | |||||||||
| Hepatitis B vaccine | 5 (2.3) | 0 | 1 | 4 (2) | 0 | 1 | 4 (2.2) | 0 | 1 |
| Influenza vaccine | 5 (2.3) | 1 (5.3) | 0.396 | 6(3) | 0 | 1 | 6 (3.2) | 0 | 1 |
P value < 0.05 showed by boldface; *previous COVID-19 within a last year; **received vaccine in the last 3 months before COVID-19 vaccination.